BIOSPECIFICS TECHNOLOGIES CORP: 10-Q filed 2017-11-09
What BIOSPECIFICS TECHNOLOGIES CORP reported in its quarterly report filed 2017-11-09 (fiscal Q3 2017): 31 published measures, 88 facts as tagged in accession 0001140361-17-041865.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-11-09
- Fiscal period
- fiscal Q3 2017
- Accession
- 0001140361-17-041865 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOSPECIFICS TECHNOLOGIES CORP filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 72,260,984 | USD | |
| At 2016-12-31 | 64,696,280 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 64,707,797 | USD | |
| At 2016-12-31 | 56,281,943 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 6,422,358 | USD | |
| At 2016-12-31 | 4,763,364 | USD | |
| At 2016-09-30 | 4,747,745 | USD | |
| At 2015-12-31 | 5,137,875 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 2,714,832 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 8,683,675 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 3,053,593 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 8,455,431 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 9,371,866 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 14,775,242 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | -358,249 | USD | 273 |
| 2016-01-01 to 2016-09-30 | -144,678 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | -7,354,623 | USD | 273 |
| 2016-01-01 to 2016-09-30 | -15,020,694 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 39,294,524 | USD | |
| At 2016-12-31 | 30,610,849 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 7,164,934 | shares | 92 |
| 2017-01-01 to 2017-09-30 | 7,166,470 | shares | 273 |
| 2016-07-01 to 2016-09-30 | 7,062,543 | shares | 92 |
| 2016-01-01 to 2016-09-30 | 7,031,068 | shares | 274 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 7,314,609 | shares | 92 |
| 2017-01-01 to 2017-09-30 | 7,325,602 | shares | 273 |
| 2016-07-01 to 2016-09-30 | 7,280,375 | shares | 92 |
| 2016-01-01 to 2016-09-30 | 7,277,780 | shares | 274 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 0.38 | USD/shares | 92 |
| 2017-01-01 to 2017-09-30 | 1.21 | USD/shares | 273 |
| 2016-07-01 to 2016-09-30 | 0.43 | USD/shares | 92 |
| 2016-01-01 to 2016-09-30 | 1.2 | USD/shares | 274 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 0.37 | USD/shares | 92 |
| 2017-01-01 to 2017-09-30 | 1.19 | USD/shares | 273 |
| 2016-07-01 to 2016-09-30 | 0.42 | USD/shares | 92 |
| 2016-01-01 to 2016-09-30 | 1.16 | USD/shares | 274 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 1,477,057 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 4,669,569 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 1,759,220 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 4,497,359 | USD | 274 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 100,428 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 100,428 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 3,983,760 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 12,876,383 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 4,725,885 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 12,714,638 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 61,566,898 | USD | |
| At 2016-12-31 | 55,399,967 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 1,997,444 | USD | |
| At 2016-12-31 | 1,996,635 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 4,681,885 | USD | |
| At 2016-12-31 | 3,810,792 | USD |
Common-stock repurchase payments
Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 616,499 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 898,025 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 356,847 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 949,359 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 312,907 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 1,005,884 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 7,164,233 | shares | |
| At 2016-12-31 | 7,156,281 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 33,303,898 | USD | |
| At 2016-12-31 | 32,945,240 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 227,868 | USD | |
| At 2016-12-31 | 258,355 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 673,064 | USD | |
| At 2016-12-31 | 624,345 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2017-09-30 | 3,000,000 | USD | |
| At 2016-12-31 | 3,300,000 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 4,191,889 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 13,353,244 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 4,812,813 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 12,952,790 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 2,175,501 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 6,916,501 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 1,843,368 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 5,909,785 | USD | 274 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 1,632,823 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 1,215,814 | USD | 274 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 14,667 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 40,651 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 6,254 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 37,448 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-07-01 to 2017-09-30 | 208,129 | USD | 92 |
| 2017-01-01 to 2017-09-30 | 476,861 | USD | 273 |
| 2016-07-01 to 2016-09-30 | 86,928 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 238,152 | USD | 274 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2017-01-01 to 2017-09-30 | 871,093 | USD | 273 |
| 2016-01-01 to 2016-09-30 | 1,298,832 | USD | 274 |
Inspect the source
- Entity
- BIOSPECIFICS TECHNOLOGIES CORP / CIK 0000875622
- Captured
- SEC response SHA-256
b1d443fa8a2de5e07d7cbcf40e33944d546011c718a394f04bbb863281862def
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000875622.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))